President Donald Trump on Monday announced he is nominating Alex Azar, a former pharmaceutical company executive and George W. Bush administration official, to succeed Tom Price as the secretary of the Department of Health and Human Services. He previously served as HHS general counsel and deputy secretary for President George W. Bush. Following his time with the administration, he worked for pharmaceutical giant Eli Lilly & Co. [He] became president of Lilly USA in 2012. As part of his role at Lilly USA, Azar was on the board of directors for the Boards of the Biotechnology Industry Organization (BIO), a drug lobbying group. In an October letter, Reps. Raul Grijalva, D-Arizona, Mark Pocan, D-Wisconsin, and Jan Schakowsky, D-Illinois, wrote that under his leadership, Azar's company fought "against federal and state legislation to increase drug pricing transparency." And a lawsuit filed in Massachusetts in early 2017 alleges that the company shot up prices on insulin "in near lock step" with two other pharmaceutical manufacturers. Following Yale Law School, Azar clerked for Supreme Court Justice Antonin Scalia, and later joined the Whitewater independent counsel headed by his "mentor" Ken Starr.
Latest
Latest News
Each news summary is created according to strict standards. Here's how we do it.
Each summary is created using a consistent editorial procedure. The target length is approximately 16 lines of 11-point Arial text in a 650-pixel-wide column. Up to 25% of a summary may be set in bold to emphasize the most important ideas. Summaries are composed of verbatim excerpts presented in the same sequence as they appear in the original news source, with very minor editorial additions. Where material has been omitted between excerpts, the omission is indicated with ellipses (...). Any words added by an editor for clarity or context appear in [brackets]. Our original news editor was Fred Burks. Tod Fletcher edited most summaries from 2007 through 2014, and Mark Bailey has served as news editor since 2014.